CervoMed (CRVO) vs ImageneBio (IMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ImageneBio (IMA) has outperformed CervoMed (CRVO) over the past year, losing 48.5% versus a loss of 63.1%. Over five years, CRVO leads with a -90.9% price change compared with -97.1% for IMA. CervoMed is the larger company by market cap ($49.6 million vs $48.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVO | IMA |
|---|---|---|
| Share price | $3.28 | $4.26 |
| Market cap | $49.59M | $48.45M |
| 1-day change | +3.14% | -7.59% |
| YTD return | -58.48% | -38.26% |
| 1-year return | -63.15% | -48.49% |
| 5-year return | -90.89% | -97.07% |
| EPS (TTM) | $-3.21 | $-4.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.00 | $9.10 |
| 52-week low | $2.13 | $3.94 |
| Distance from 52-week high | -67.20% | -53.19% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +369.51% | +322.54% |
| Average volume | 339.08K | 13.04K |
| Shares outstanding | 15.12M | 11.37M |
| Employees | 15 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMA has outperformed CRVO by 14.7 percentage points over the past year.
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Healthcare · Biotechnology · 15 employees
About ImageneBio
IMA stock →ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Healthcare · Biotechnology · 18 employees
CRVO vs IMA FAQ
Which is bigger, CervoMed or ImageneBio?
CervoMed (CRVO) is larger, with a market capitalization of $49.59M compared with $48.45M for ImageneBio (IMA).
Which stock has performed better over the past year, CRVO or IMA?
IMA returned -48.49% over the past 12 months, compared with -63.15% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are CervoMed and ImageneBio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.